跳至主要内容
临床试验/NCT04844008
NCT04844008撤回不适用

An Investigation of Whether Orally Delivered Nanobubbles Have a Physiological Effect on Joint Hypoxia?

University of Oxford2 个研究点 分布在 1 个国家开始时间: 2021年10月5日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Change in Synovial fluid pO2

研究概览

简要总结

Inflamed joints in patients with rheumatoid arthritis and psoriatic arthritis are characterized by low oxygen levels and inflammation. We propose to investigate whether tiny bubbles (nanobubbles) when given in a drink can alter oxygen level in joints. These nanobubbles are so small that they can enter the bloodstream when given as a drink. This information will give new information on the role of oxygen in joint inflammation and could possibly lead to new treatment approaches in the future.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 18 years or above.
  • Fulfil American College of Rheumatology/European League Against Rheumatism criteria (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria or fulfil Classification Criteria for Psoriatic Arthritis 2006 (CASPAR).
  • Selected joint for biopsy must be minimum Grade 2 synovial thickening for large joint (knee) and medium joint (wrist), or minimum Grade 3 synovial thickening for small joint (metacarpophalangeal).
  • Women of child bearing potential who are willing to use effective contraception (i.e. barrier, oral contraceptive pill, implanted contraception, or previous hysterectomy, bilateral oophorectomy) for the duration of the study.

排除标准

  • • Currently on oxygen therapy.
  • Current enrolment in any other clinical study involving an investigational study treatment.
  • Pregnant or lactating, or women planning to become pregnant or initiating breastfeeding.
  • Intramuscular, intravenous or intra-articular administration of corticosteroid within 4 weeks prior to baseline visit.
  • Oral corticosteroid > 10 mg/day prednisolone or equivalent within 4 weeks prior to baseline visit.
  • Oral corticosteroid dose not stable for at least 4 weeks prior to baseline visit.
  • Oral non-steroidal anti-inflammatory drugs (including aspirin > 75 mg/ day and selective-cyclooxygenase inhibitors) dose not stable for at least 4 weeks prior to baseline visit.
  • Disease modifying anti-rheumatic drugs (DMARDs) dose not stable for at least 4 weeks prior to baseline visit.
  • History of septic arthritis.
  • Participants on warfarin, heparin, low molecular weight heparin, direct oral anticoagulants. Oral anti-platelet agents are permitted.
  • History of haemophilia.

结局指标

主要结局

Change in Synovial fluid pO2

时间窗: Change in synovial fluid pO2 between day 1 and day 28

次要结局

  • Change in hypoxia-inducible factor 1α (HIF-1α) protein levels in synovial tissues(Change in hypoxia-inducible factor 1α (HIF-1α) protein between day 1 and day 28)
  • Treatment Satisfaction Questionnaire for Medication (C)(Day28)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验